{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001802768","name":"Royalty Pharma plc","summary":"Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, founded in 1996. It acquires royalties entitling it to payments based on top-line sales of leading therapies including Vertex's Trikafta, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Xtandi, Tremfya, Imbruvica, Trodelvy, Amvuttra, and others. As of December 31, 2025, its portfolio includes royalties on more than 35 marketed products and 20 development-stage candidates, generating $3.3 billion in Portfolio Receipts in 2025.","people":[],"products":[{"name":"Trikafta/Alyftrek royalty","type":"service","description":"Royalty on Vertex's cystic fibrosis franchise, largest marketed royalty in 2025"},{"name":"Trelegy royalty","type":"service","description":"Royalty on GSK's respiratory therapy"},{"name":"Tysabri royalty","type":"service","description":"Royalty on Biogen's neuroscience therapy"},{"name":"Spinraza royalty","type":"service","description":"Royalty on Biogen's therapy for spinal muscular atrophy"},{"name":"Evrysdi royalty","type":"service","description":"Royalty on Roche's therapy"},{"name":"Xtandi royalty","type":"service","description":"Royalty on Astellas and Pfizer's oncology therapy"},{"name":"Tremfya royalty","type":"service","description":"Royalty on Johnson & Johnson's immunology therapy"},{"name":"Imbruvica royalty","type":"service","description":"Royalty on AbbVie and Johnson & Johnson's hematology therapy"},{"name":"Voranigo royalty","type":"service","description":"Royalty on Servier's oncology therapy"},{"name":"Trodelvy royalty","type":"service","description":"Royalty on Gilead's oncology therapy"},{"name":"Imdelltra royalty","type":"service","description":"Royalty on Amgen's oncology therapy"},{"name":"Amvuttra royalty","type":"service","description":"Royalty on Alnylam's rare disease therapy"}],"partnerships":[{"partner_name":"Vertex","partnership_type":"licensing","description":"Royalty on cystic fibrosis franchise including Trikafta and Alyftrek","start_date":null},{"partner_name":"GSK","partnership_type":"licensing","description":"Royalty on Trelegy respiratory therapy","start_date":null},{"partner_name":"Biogen","partnership_type":"licensing","description":"Royalties on Tysabri and Spinraza","start_date":null},{"partner_name":"Roche","partnership_type":"licensing","description":"Royalty on Evrysdi","start_date":null},{"partner_name":"Astellas","partnership_type":"licensing","description":"Royalty on Xtandi oncology therapy","start_date":null},{"partner_name":"Pfizer","partnership_type":"licensing","description":"Royalty on Xtandi oncology therapy","start_date":null},{"partner_name":"Johnson & Johnson","partnership_type":"licensing","description":"Royalties on Tremfya and Imbruvica","start_date":null},{"partner_name":"AbbVie","partnership_type":"licensing","description":"Royalty on Imbruvica hematology therapy","start_date":null},{"partner_name":"Servier","partnership_type":"licensing","description":"Royalty on Voranigo oncology therapy","start_date":null},{"partner_name":"Gilead","partnership_type":"licensing","description":"Royalty on Trodelvy oncology therapy","start_date":null},{"partner_name":"Amgen","partnership_type":"licensing","description":"Royalty on Imdelltra oncology therapy","start_date":null},{"partner_name":"Alnylam","partnership_type":"licensing","description":"Royalty on Amvuttra rare disease therapy","start_date":null},{"partner_name":"MorphoSys","partnership_type":"development","description":"Held Development Funding Bonds; sold for $511 million in proceeds in 2025","start_date":null}],"affiliations":[],"origin":{"leaf":"7caf624eb0b66f7c5ef83d83694e6733de5647ae4d9725d7701ebd6f82a2bd64","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"1ce3203e9505db143886b74f1db89fb7f734267ddc77c4c8c9cb5ff460dc4c75","parent":"013cbefafe05b523525ea0bf36977e442dc92722d6fcb9fd329f09e803b40922","source":"0001802768-26-000003","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}